Access to Medicines and Pharmaceutical Policy in Saudi Arabia: A Scoping Review

References

• The National Medicines Policy. A partnership for better health outcomes. National Medicines Policy Document; 2014.
   Google Scholar
• Almarsdottir AB, Traulsen JM. Studying and evaluating pharmaceutical policy becoming a part of the policy and consultative process. Pharm World Sci. 2006;28:6–12. doi:10.1007/s11096-006-9011-0
   PubMedGoogle Scholar
• Mossialos E, Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, The Netherlands and the United Kingdom. Int J Health Plann Manag. 2005;20:291–306. doi:10.1002/hpm.816
   PubMed Web of Science ®Google Scholar
• Wonder M, Milne R. Access to new medicines in New Zealand compared to Australia. N Med J. 2011;124:12–28.
   Google Scholar
• GMI Blogger. Saudi Arabia population statistics 2023 [Infographics]; 2023. Available from: https://www.globalmediainsight.com/blog/saudi-arabia-population-statistics/. Accessed June 12, 2022.
   Google Scholar
• Ahmed M. Healthcare opportunities and challenges in Saudi Arabia 2020; 2021. Available from: https://insights.omnia-health.com/reports/healthcare-opportunities-and-challenges-saudi-arabia. Accessed July 5, 2023.
   Google Scholar
• Almalki M, FitzGerald G, Clark M. Health care system in Saudi Arabia: an overview. EMHJ. 2011;17(10):784–793. doi:10.26719/2011.17.10.784
   Google Scholar
• Organizations’ USDoCot. Healthcare resource guide. Saudi Arabia; 2019.
   Google Scholar
• Almutairi KM. Culture and language differences as a barrier to provision of quality care by the health workforce in Saudi Arabia. Saudi Med J. 2015;36(4):425. doi:10.15537/smj.2015.4.10133
   PubMed Web of Science ®Google Scholar
• Center R. Drug shortages in Saudi Arabia: root causes and recommendations; 2018.
   Google Scholar
• AlTamimi A, Malhis NK, Khojah NM, Manea SA, AlTamimi A, AlShammary SA. Antidote availability in Saudi Arabia hospitals in the Riyadh Province. Basic Clin Pharmacol Toxicol. 2018;122(2):288–292. doi:10.1111/bcpt.12897
   PubMed Web of Science ®Google Scholar
• Almaghaslah D, Alsayari A, Asiri R, Albugami N. Pharmacy workforce in Saudi Arabia: challenges and opportunities: a cross‐sectional study. Int J Health Plann Manage. 2019;34(1):e583–e93. doi:10.1002/hpm.2674
   PubMed Web of Science ®Google Scholar
• Almaghaslah D, Alsayari A, Almaghaslah S, Alsanna H. Patients’ satisfaction with E-Prescribing (Wasfaty) in Saudi Arabia: a survey of country-level implementation. InHealthcare. 2022;10(5):806. doi:10.3390/healthcare10050806
   Web of Science ®Google Scholar
• Morrow NC, LeCates RF, Zhang F, Ross-Degnan D. Pharmaceutical policy Part 1 The challenge to pharmacists to engage in policy development. J Pharm Policy Pract. 2015;8(1):1–5. doi:10.1186/s40545-014-0024-0
   PubMedGoogle Scholar
• Rasooldeen M. Saudi Arabia aims to boost pharmaceutical industry. Arab News (Jeddah, Saudi Arabia); 2017.
   Google Scholar
• export.gov. Saudi Arabia - pharma and biosciences 2020; 2020. Available from: https://www.export.gov/apex/article2?id=Saudi-Arabia-Pharma-and-Biosciences. Accessed July 5, 2023.
   Google Scholar
• Administration it. Saudi Arabia - country commercial guide 2019; 2019. Available from: https://www.trade.gov/knowledge-product/saudi-arabia-pharma-and-biosciences. Accessed July 5, 2023.
   Google Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–473. doi:10.7326/M18-0850
   PubMed Web of Science ®Google Scholar
• Penchansky R, Thomas JW. The concept of access: definition and relationship to consumer satisfaction. Med Care. 1981;19:127–140. doi:10.1097/00005650-198102000-00001
   PubMed Web of Science ®Google Scholar
• Alkhuzaee FS, Almalki HM, Attar AY, et al. Evaluating community pharmacists’ perspectives and practices concerning generic medicines substitution in Saudi Arabia: a cross-sectional study. Health Policy (New York). 2016;120(12):1412–1419. doi:10.1016/j.healthpol.2016.09.018
   Web of Science ®Google Scholar
• Salhia HO, Ali A, Rezk NL, El Metwally A. Perception and attitude of physicians toward local generic medicines in Saudi Arabia: a questionnaire-based study. Saudi Pharmaceut J. 2015;23(4):397–404. doi:10.1016/j.jsps.2015.01.014
   PubMed Web of Science ®Google Scholar
• Alruthia YS, Alwhaibi M, Alotaibi MF, et al. Drug shortages in Saudi Arabia: root causes and recommendations. Saudi Pharmaceut J. 2018;26(7):947–951. doi:10.1016/j.jsps.2018.05.002
   PubMed Web of Science ®Google Scholar
• AlRuthia YS, AlKofide H, AlAjmi R, et al. Drug shortages in large hospitals in Riyadh: a cross-sectional study. Ann Saudi Med. 2017;37(5):375–385. doi:10.5144/0256-4947.2017.375
   PubMed Web of Science ®Google Scholar
• Al Saffer Q, Al-Ghaith T, Alshehri A, et al. The capacity of primary health care facilities in Saudi Arabia: infrastructure, services, drug availability, and human resources. BMC Health Serv Res. 2021;21(1):1–15. doi:10.1186/s12913-021-06355-x
   PubMed Web of Science ®Google Scholar
• Al-Ruthia YS, Mansy W, Barasin M, et al. Shortage of psychotropic medications in community pharmacies in Saudi Arabia: causes and solutions. Saudi Pharmaceut J. 2017;25(5):744–749. doi:10.1016/j.jsps.2016.10.013
   PubMed Web of Science ®Google Scholar
• Alsheikh M, Seoane-Vazquez E, Rittenhouse B, Fox ER, Fanikos J. A comparison of drug shortages in the hospital setting in the United States and Saudi Arabia: an exploratory analysis. Hosp Pharm. 2016;51(5):370–375. doi:10.1310/hpj5105-370
   PubMedGoogle Scholar
• AlAzmi A, AlRashidi F. Medication Exchange and Sharing Network Program (MESNP) initiative to cope with drug shortages in the Kingdom of Saudi Arabia (KSA). Risk Manag Healthc Policy. 2019;12:115. doi:10.2147/RMHP.S198375
   PubMed Web of Science ®Google Scholar
• Alsheikh MY, Alzahrani MA, Alsharif NA, et al. Community pharmacy staff knowledge, opinion and practice toward drug shortages in Saudi Arabia. Saudi Pharmaceut J. 2021;29:1383–1391. doi:10.1016/j.jsps.2021.09.001
   PubMed Web of Science ®Google Scholar
• Al-Omar HA. Cost-conscious medications-prescribing behavior among physicians working in Saudi Arabia. Arch Pharm Pract. 2020;1:143.
   Google Scholar
• Al-Omar HA, Attuwaijri AA, Aljuffali IA. What local experts expect from a health technology assessment (HTA) entity in Saudi Arabia: workshop conclusions. Expert Rev Pharmacoecon Outcomes Res. 2020;20(1):99–104. doi:10.1080/14737167.2019.1610398
   PubMed Web of Science ®Google Scholar
• Al-Omar HA, Aljuffali IA, Solà-Morales O. Value drivers for pharmaceutical products in health technology assessment (HTA) in Saudi Arabia: results from a capacity building, multi-stakeholder workshop. Saudi Pharmaceut J. 2021;29(9):946–954. doi:10.1016/j.jsps.2021.08.001
   PubMed Web of Science ®Google Scholar
• Alsultan MS. The role of pharmacoeconomics in formulary decision making in different hospitals in Riyadh, Saudi Arabia. Saudi Pharmaceut J. 2011;19(1):51–56. doi:10.1016/j.jsps.2010.10.005
   PubMed Web of Science ®Google Scholar
• Omair MA, Alhawassi T, Alwaihibi M, et al. Improving the understanding of originator and biosimilar biologics among healthcare providers in Saudi Arabia. Saudi Pharmaceut J. 2020;28(12):1827–1829. doi:10.1016/j.jsps.2020.11.008
   PubMed Web of Science ®Google Scholar
• Almahdi FB, Hashim AH, Albaba EAM, et al. The Impact of the pharmaceutical care management model of Hepatitis C medications on the cost at health insurance level. Value Health Reg Issues. 2020;21:230–237. doi:10.1016/j.vhri.2020.01.004
   PubMedGoogle Scholar
• Bawazir SA, Alkudsi MA, Al Humaidan AS, Al Jaser MA, Sasich LD. Pharmaceutical policies used by private health insurance companies in Saudi Arabia. Saudi Pharmaceut J. 2013;21(3):267–276. doi:10.1016/j.jsps.2012.10.005
   PubMed Web of Science ®Google Scholar
• Balkhi B, Alqahtani S, Altayyar W, et al. Drug utilization and expenditure of anticancer drugs for breast cancer. Saudi Pharmaceut J. 2020;28(6):669–674. doi:10.1016/j.jsps.2020.04.007
   PubMed Web of Science ®Google Scholar
• Alkhudair N, Alshamrani M, Samarkandi H, et al. Cancer management in Saudi Arabia: recommendations by the Saudi Oncology Health Economics Expert Group (SHARP). Saudi Pharmaceut J. 2021;29(2):115–120. doi:10.1016/j.jsps.2020.12.005
   PubMed Web of Science ®Google Scholar
• Khan TM, Emeka P, Suleiman AK, Alnutafy FS, Aljadhey H. Pharmaceutical pricing policies and procedures in Saudi Arabia: a narrative review. Ther Innov Regul Sci. 2016;50(2):236–240. doi:10.1177/2168479015609648
   PubMed Web of Science ®Google Scholar
• Hassali MA, AlRasheedy AA, Mclachlan A, et al. The experiences of implementing generic medicine policy in eight countries: a review and recommendations for a successful promotion of generic medicine use. Saudi Pharmaceut J. 2014;22:491–503. doi:10.1016/j.jsps.2013.12.017
   PubMed Web of Science ®Google Scholar
• Kurdi S, Faran A, Eareeni E, et al. Assessment of knowledge and attitude toward the new antibiotic dispensing law and its effect on antibiotic use in Saudi Arabia. Saudi Pharmaceut J. 2020;28(1):58–67. doi:10.1016/j.jsps.2019.11.005
   PubMed Web of Science ®Google Scholar
• Vogler S, Kilpatrick K, Babar Z-U-D. Analysis of medicine prices in New Zealand and 16 European countries. Value Health. 2015;18:484–492. doi:10.1016/j.jval.2015.01.003
   PubMed Web of Science ®Google Scholar
• Zia N, Ibrahim MI, Adheir F, Babar Z-U-D. Identifying priority medicines policy issues for Qatar: exploring perspectives and experiences of healthcare professionals through a qualitative study. BMJ open. 2021;11(11):e054150. doi:10.1136/bmjopen-2021-054150
   PubMed Web of Science ®Google Scholar
• Kamphuis BW, Kanavos P. Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration. Health Policy OPEN. 2021;2:100045. doi:10.1016/j.hpopen.2021.100045
   PubMedGoogle Scholar
• ABPI. Why is it important to improve access to medicine in the UK?; 2019 Available from: https://www.abpi.org.uk/what-we-do/medicine-pricing-in-The-uk/why-is-it-important-to-improve-access-to-medicine-inthe-uk/. Accessed July 5, 2023.
   Google Scholar
• Takayama A, Narukawa M. Comparison of new drug accessibility and price between Japan and major European countries. Ther Innov Regul Sci. 2017;51:604–611. doi:10.1177/2168479017706716
   PubMed Web of Science ®Google Scholar
• Tawfik EA, Tawfik AF, Alajmi AM, et al. Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia. Saudi Pharmaceut J. 2021;2021:1.
   Google Scholar